Earnings Routine +

Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA Superscript 2 and $32.0 Million in Working Capital

Hydreight's Q1 EBITDA Margin Expansion Validates Operating Leverage, But Valuation Premium Demands Flawless Execution

By The Northwire Desk — AI Analysis Jun 01, 2026 · 21:32 NURS · 4.73 Hydreight Technologies Inc.

Executive Summary

Hydreight reported record Q1 2026 financials, with GAAP revenue of $24.93M, representing a 449% year-over-year increase.
Adjusted EBITDA surged 1,412% YoY to $3.26M, expanding the Adjusted EBITDA margin to 13.1% from 3.6% in Q1 2025.
The balance sheet is robust, ending the quarter with $24.2M in cash, $32.0M in working capital, and $36.4M in shareholders' equity.
Management reaffirmed full-year 2026 guidance of approximately $150M in revenue, citing expanding operating leverage and strategic investments in the VSDHOne platform and pharmacy infrastructure.
Operational metrics show over 12,000 VSDHOne licenses sold, operations active in all 50 U.S. states, and a network of 3,000+ nurses and 300+ doctors.
VSDHOne 2.0 development is focused on scalability, automation, and patient-specific workflows, alongside strategic pharmacy infrastructure expansion.

Material Impact

The Q1 2026 results align with the aggressive growth trajectory established in late 2025 and early 2026. Revenue of $24.93M sits just below the low end of the $25M-$28M Q1 guidance range, indicating disciplined execution rather than a surprise beat.
The 13.1% Adjusted EBITDA margin demonstrates that the company is successfully capturing operating leverage as transaction volumes scale, a critical inflection point for platform-based healthcare models.
Historical progression shows a clear maturation: Q3 2025 posted a $620K EBITDA on $10.5M revenue; Q4 2025 improved to $1.58M EBITDA on $14.95M revenue; FY 2025 closed at $2.5M EBITDA on $35.4M revenue. Q1 2026 continues this upward trajectory, proving the VSDHOne platform is transitioning from a growth phase to a profitability phase.
While the growth is impressive, the slight miss on the top-end of Q1 guidance and the fact that an annualized run rate of ~$100M still trails the $150M full-year target suggests Q2-Q4 must accelerate significantly. The market has already priced in much of this growth through the stock's recovery from $2.70 in March to $4.73 in June.
The news is routine in nature as it is a standard quarterly earnings release that confirms existing guidance and prior operational momentum. It does not contain genuinely new, unexpected catalysts that would fundamentally alter the company's valuation thesis.

NURS · Price

Company Overview

Hydreight Technologies operates a national digital health and pharmacy infrastructure platform designed to streamline access to wellness and medical treatments across the United States.
Flagship Project: VSDHOne, a direct-to-consumer telehealth platform that enables brands and healthcare providers to launch compliant services across all 50 states rapidly. The platform integrates nurse/doctor networks, state-by-state telehealth compliance, and 503A/503B pharmacy fulfillment.
The company has expanded into high-demand verticals including GLP-1 weight management, hormone therapy, NAD+, hair restoration, and at-home STI testing, leveraging its integrated care flow from pre-screening to clinical consultation and pharmacy fulfillment.

More from Hydreight Technologies Inc.